ESR1 and breast carcinoma: Drug-druginteractions are another aspect that physicians will need to be aware of.Bonofiglio’s PPARγ-ER-PTEN results are significant in the contextof breast cancer and hormone therapies [22].Their data suggest that women treated with hormones, either through birthcontrol or hormonal therapies, may not benefit from cotreatment with a PPARγ agonist.